Spring Creek Capital’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Spring Creek Capital’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,333	Closed	-$26K	–	476
2022 Q1	$26K	Hold	33,333	–	–	﹤0.01%	674
2021 Q4	$20K	Hold	33,333	–	–	﹤0.01%	641
2021 Q3	$32K	Hold	33,333	–	–	﹤0.01%	530
2021 Q2	$49K	Buy	+33,333	New	+$29.1K	﹤0.01%	501

Other funds holding PEARW

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

OCAM

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

AGC

Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

SRF

Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return

Spring Creek Capital's PEARW Position: Q2 2022 in Review

Spring Creek Capital sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2022, closing a stake of 33,333 shares — an estimated $26K sold.

Spring Creek Capital first reported a position in PEARW in Q2 2021 and held it in 4 quarters. The position peaked at $49K in Q2 2021. 37 funds tracked by Wall St. Rank hold PEARW as of Q2 2022.

Spring Creek Capital reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2022 after selling out during the quarter.
Spring Creek Capital sold 33,333 Pear Therapeutics, Inc. Warrant shares in Q2 2022, an estimated $26K.
Spring Creek Capital first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 4 quarters.
Spring Creek Capital's Pear Therapeutics, Inc. Warrant position peaked at $49K in Q2 2021.
37 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.